How to solve manufacturing scale-up problems before they become regulatory problems
Manufacturing scale-up is one of the highest-risk transitions in pharmaceutical development.
Moving a process from lab to pilot plant, or from pilot scale to commercial manufacturing, rarely happens without technical challenges. Those challenges, if they surface during or after regulatory review, become considerably more expensive to resolve.
The distinction between a scale-up problem and a regulatory problem is narrower than most development teams appreciate. Understanding how they connect is the first step to managing both.
Why scale-up problems become regulatory problems
The connection between manufacturing scale-up and regulatory risk is direct.
When a process changes at scale, the product can change with it. Particle size distribution, dissolution profile, impurity levels, physical form: any of these can shift in ways that affect both product quality and regulatory status. If those changes are not characterised, justified and documented before submission, they create vulnerabilities in the CMC package that agencies will find.
Agencies review scale-up data carefully. A process characterisation package that does not convincingly demonstrate equivalence between development and commercial batches will generate questions. In the worst case, it requires additional manufacturing runs, comparability studies, or analytical work before the submission can proceed.
The regulatory risk is not a consequence of scale-up itself. It is a consequence of how scale-up is managed and documented.
Scale-up as a regulatory exercise
Agencies expect to see evidence that the developer understands their process at scale
Quality must be demonstrated as built in, not tested in after the fact
Comparability between development and commercial batches must be explicitly established
The CMC narrative must tie the development history to the commercial process clearly
Have a scale-up campaign or technology transfer coming up?
TDP's manufacturing sciences and technology consultants work alongside development teams at scale-up and technology transfer. Contact us before your campaign starts.
Where MS&T expertise adds the most value
Manufacturing sciences and technology expertise bridges the gap between process development and the regulatory-quality documentation that submissions require.
At the scale-up stage, that means identifying critical process parameters and critical quality attributes before moving to larger scale, designing scale-up studies with regulatory expectations explicitly in mind, managing CDMO relationships through the technical transfer process, building the data packages that support process validation and the control strategy, and ensuring that what happens on the manufacturing floor is accurately reflected in the CMC narrative.
The difference between a scale-up programme that runs smoothly and one that creates regulatory delays often comes down to whether MS&T thinking was embedded from the start, or brought in to fix problems after the fact.
The CDMO relationship and the documentation gap
Most development-stage pharmaceutical companies do not manufacture internally. They work with CDMOs, which introduces an additional layer of complexity into scale-up management.
CDMOs are capable manufacturers. Their focus is on the manufacturing process. The burden of ensuring that process is documented to regulatory standards, and that it ties coherently to the development history, sits with your team.
Without active MS&T oversight, CDMO-managed scale-up programmes frequently produce strong manufacturing outcomes and weak CMC documentation. The process worked. The data package does not tell the story the agency needs to see. That gap is where regulatory delays originate.
Questions to ask before a CDMO-managed scale-up campaign
Who is responsible for ensuring the manufacturing data maps to regulatory CMC requirements?
Have comparability criteria been defined before the campaign, not after?
Is there a process characterisation strategy in place that anticipates likely agency questions?
How will analytical method transfer and validation at the receiving site be overseen?
Who is accountable for the CMC narrative that ties the campaign to the development history?
What proactive scale-up planning looks like
Effective scale-up planning starts well before the manufacturing campaign begins.
1. A technical transfer plan built around CMC requirements
Define what data will be generated and how it maps to the CMC package before the campaign starts. This determines what gets measured, not what gets reported after the fact.
2. Comparability criteria agreed before, not after
Define what comparability looks like before the campaign. If you are agreeing what counts as success after the data is in hand, you have already lost the argument with a regulator.
3. A process characterisation strategy designed for agency review
Understand what the agency will want to see in the process characterisation package. Design the studies accordingly, not retrospectively.
4. Analytical oversight at the receiving site
Analytical method transfer and validation at the CDMO is one of the most common sources of CMC gaps. It needs dedicated oversight, not assumption.
5. Structured checkpoints between MS&T, regulatory and the CDMO
Cross-functional alignment at defined points in the campaign avoids the siloed working that produces good manufacturing data and poor CMC documentation.
This kind of structured approach does not add time to the programme. It removes the rework that occurs when scale-up issues are discovered late, when options are limited and timelines are already fixed.
Scale-up problems found during regulatory review are expensive. Found before submission, they are manageable.
TDP provides MS&T consulting support at scale-up and technology transfer. If you have a manufacturing campaign ahead of a regulatory filing, we should talk before the campaign starts.
When to bring in external MS&T support
Not every development-stage company has in-house MS&T capability at the level a demanding scale-up programme requires. Even where internal resource exists, there are moments where additional depth makes the difference: a novel dosage form, a technically complex technology transfer, a tight regulatory timeline with little room for rework.
External MS&T support works best when it is integrated with your team rather than operating at arm's length. It should cover both the technical and the regulatory dimensions of scale-up, and it should be led by people who have directly managed scale-up programmes through to regulatory approval.
The investment in getting scale-up right is modest relative to the cost of managing a scale-up problem during regulatory review. The earlier expert input is brought in, the more it can shape the programme rather than respond to it.
If you have a scale-up campaign or technology transfer approaching, we are happy to give you a direct view on where the regulatory risks sit.